应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
COR CENCORA
盘后交易 09-30 19:30:25 EDT
300.25
-7.35
-2.39%
盘后
300.25
+0.00
0.00%
19:30 EDT
最高
306.40
最低
295.01
成交量
181.11万
今开
306.40
昨收
307.60
日振幅
3.70%
总市值
572.96亿
流通市值
548.45亿
总股本
1.91亿
成交额
5.45亿
换手率
0.99%
流通股本
1.83亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读｜Cencora盘中下跌3.3%，报297.615美元
行情直击 · 09-30 21:43
异动解读｜Cencora盘中下跌3.3%，报297.615美元
异动解读｜Cencora盘前下跌3.22%，报307.72美元
行情直击 · 09-30 20:23
异动解读｜Cencora盘前下跌3.22%，报307.72美元
高基数与银保新政双重施压，人身险累计保费增速年内首度转负
第一财经 · 09-28 20:49
高基数与银保新政双重施压，人身险累计保费增速年内首度转负
异动解读｜Cencora盘中下跌3.77%，GLP-1产品组合对利润率的拖累持续承压
行情直击 · 08-13
异动解读｜Cencora盘中下跌3.77%，GLP-1产品组合对利润率的拖累持续承压
异动解读｜Cencora盘中上涨3.78%，Q3业绩超预期并上调全年盈利指引
行情直击 · 08-06
异动解读｜Cencora盘中上涨3.78%，Q3业绩超预期并上调全年盈利指引
异动解读 | 业绩超预期并上调全年盈利指引，Cencora盘中大涨5.21%
异动解读 · 08-05
异动解读 | 业绩超预期并上调全年盈利指引，Cencora盘中大涨5.21%
Cencora高管：聚焦视网膜与肿瘤领域，推进增值型“补强式”收购——电话会议纪要
美股速递 · 08-05
Cencora高管：聚焦视网膜与肿瘤领域，推进增值型“补强式”收购——电话会议纪要
CENCORA高管：我们的重点是在视网膜和肿瘤领域进行增值性补强收购。
智通财经 · 08-05
CENCORA高管：我们的重点是在视网膜和肿瘤领域进行增值性补强收购。
Cencora首席财务官：Mwi Animal Health与Covetrus合并若完成，将带来1.5亿美元营业利润压力——电话会议实录
美股速递 · 08-05
Cencora首席财务官：Mwi Animal Health与Covetrus合并若完成，将带来1.5亿美元营业利润压力——电话会议实录
异动解读｜Cencora盘前上涨3.25%，多重利好催化持续发酵
行情直击 · 07-17
异动解读｜Cencora盘前上涨3.25%，多重利好催化持续发酵
Cencora与Kite达成协议，支持其FDA批准的CAR-T细胞疗法Yescarta与Tecartus在美国的分销
美股速递 · 06-02
Cencora与Kite达成协议，支持其FDA批准的CAR-T细胞疗法Yescarta与Tecartus在美国的分销
Cencora公司执行副总裁兼首席财务官James F. Cleary将退休，并担任顾问至2026年
美股速递 · 05-27
Cencora公司执行副总裁兼首席财务官James F. Cleary将退休，并担任顾问至2026年
市场资金在切换，这个方向或迎来大反攻？
格隆汇 · 05-24
市场资金在切换，这个方向或迎来大反攻？
Cencora高管：公司看好管理服务组织业务的长期并购机遇——电话会议透露
美股速递 · 05-06
Cencora高管：公司看好管理服务组织业务的长期并购机遇——电话会议透露
【研报掘金｜华泰证券：上调中国再保险目标价至1.1港元 去年盈利超预期】华泰证券发表研究报告指，中国再保险预计2024年归母净利润按年升80%至100%，超出该行预期。该行认为，公司利润高速增长，或主要受投资业绩高增以及保险业务稳健增长的驱动。该行预计，集团2024年人身再保险业务净利润有望增长236%，2024年全年财险业务COR达99.8%。该行表示，考虑到投资波动，将上年、今年及明年每股盈测上调至分别0.25元、0.21元及0.21元，目标价则由1港元上调至1.1港元，维持其评级为“买入”。
金融界 · 2025-02-24
【研报掘金｜华泰证券：上调中国再保险目标价至1.1港元 去年盈利超预期】华泰证券发表研究报告指，中国再保险预计2024年归母净利润按年升80%至100%，超出该行预期。该行认为，公司利润高速增长，或主要受投资业绩高增以及保险业务稳健增长的驱动。该行预计，集团2024年人身再保险业务净利润有望增长236%，2024年全年财险业务COR达99.8%。该行表示，考虑到投资波动，将上年、今年及明年每股盈测上调至分别0.25元、0.21元及0.21元，目标价则由1港元上调至1.1港元，维持其评级为“买入”。
【沃尔格林联合博姿继续出售Cencora股份 套现约3亿美元】 美国连锁药店沃尔格林联合博姿周四表示，已出售更多药品分销商Cencora的股份，套现约3亿美元。该公司目前在Cencora的持股比例从10%降至6%。此次出售股份所得将主要用于偿还债务和一般公司用途。（智通财经）
金融界 · 2025-02-07
【沃尔格林联合博姿继续出售Cencora股份 套现约3亿美元】 美国连锁药店沃尔格林联合博姿周四表示，已出售更多药品分销商Cencora的股份，套现约3亿美元。该公司目前在Cencora的持股比例从10%降至6%。此次出售股份所得将主要用于偿还债务和一般公司用途。（智通财经）
Cencora 第一季度财报：肥胖药物和特殊药品推动收入和每股收益超预期
财报速递 · 2025-02-06
Cencora 第一季度财报：肥胖药物和特殊药品推动收入和每股收益超预期
Cencora(COR.US)：2025年Q1财报实现营收814.87亿美元，前值为722.53亿美元，预期值为782.2亿美元；每股收益为3.73美元，前值为3.28美元，预期值为3.52美元。
金融界 · 2025-02-05
Cencora(COR.US)：2025年Q1财报实现营收814.87亿美元，前值为722.53亿美元，预期值为782.2亿美元；每股收益为3.73美元，前值为3.28美元，预期值为3.52美元。
Cencora 2025年第一季度调整后每股收益$3.73，超过预期的$3.50，销售额为$814.9亿，超过预期的$783.8亿
财报速递 · 2025-02-05
Cencora 2025年第一季度调整后每股收益$3.73，超过预期的$3.50，销售额为$814.9亿，超过预期的$783.8亿
富国银行：维持Cencora(COR.US)评级，由持股观望调整至持股观望评级, 目标价由237.00美元调整至251.00美元。
金融界 · 2025-01-29
富国银行：维持Cencora(COR.US)评级，由持股观望调整至持股观望评级, 目标价由237.00美元调整至251.00美元。
加载更多
公司概况
公司名称：
CENCORA
所属市场：
NYSE
上市日期：
--
主营业务：
Cencora, Inc.于2001年3月在特拉华州注册成立。作为全球最大的药品采购和分销服务公司之一，帮助医疗保健供应商以及制药和生物技术制造商改善患者获得产品加强患者护理的机会。该公司提供创新计划和服务，旨在提高药品供应链在人类和动物健康方面的效力和效率。更具体地说，该公司向位于美国和部分全球市场的各种医疗保健提供商提供全面的品牌、专业品牌和非专利药品、非处方医疗产品、家庭医疗用品和设备以及相关服务，包括急性病医院和卫生系统、独立和连锁零售药店、邮购药房、诊所、长期护理和替代地点药房、医师执业、医疗和透析诊所、兽医和其他客户。此外，公司还为医疗保健提供商和制药制造商提供各种相关服务，包括数据分析、结果研究、报销和药物咨询服务、利基优质物流服务、库存管理、药房自动化、药房管理和包装解决方案。
发行价格：
--
{"stockData":{"symbol":"COR","market":"US","secType":"STK","nameCN":"CENCORA","latestPrice":300.25,"timestamp":1790798400000,"preClose":307.6,"halted":0,"volume":1811105,"hourTrading":{"tag":"盘后","latestPrice":300.25,"preClose":300.25,"latestTime":"19:30 EDT","volume":159036,"amount":47750485.84344,"timestamp":1790811007512,"change":0,"changeRate":0,"amplitude":0.007897},"delay":0,"changeRate":-0.02389466840052023,"floatShares":182663230,"shares":190827165,"eps":13.461243,"marketStatus":"盘后交易","change":-7.35,"latestTime":"09-30 19:30:25 EDT","open":306.4,"high":306.4,"low":295.01,"amount":545096295.0451499,"amplitude":0.037029,"askPrice":305.41,"askSize":54,"bidPrice":300.3,"bidSize":10,"shortable":3,"etf":0,"ttmEps":13.461243,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1790812800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1285214400000,"exchange":"NYSE","adjPreClose":307.6,"dividendRate":0.007827,"preHourTrading":{"tag":"盘前","latestPrice":307,"preClose":307.6,"latestTime":"09:29 EDT","volume":146,"amount":43648.06509999999,"timestamp":1790774988071,"change":-0.6,"changeRate":-0.001951,"amplitude":0.004976},"postHourTrading":{"tag":"盘后","latestPrice":300.25,"preClose":300.25,"latestTime":"19:30 EDT","volume":159036,"amount":47750485.84344,"timestamp":1790811007512,"change":0,"changeRate":0,"amplitude":0.007897},"volumeRatio":1.49473,"impliedVol":0.307,"impliedVolPercentile":0.6295},"requestUrl":"/m/hq/s/COR","defaultTab":"news","newsList":[{"id":"1193509665","title":"异动解读｜Cencora盘中下跌3.3%，报297.615美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193509665","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193509665?lang=zh_cn&edition=full","pubTime":"2026-09-30 21:43","pubTimestamp":1790775805,"startTime":"0","endTime":"0","summary":"9月30日，Cencora盘中下跌3.3%，报297.615美元/股，成交额2517.63万美元。Cencora所在的保健护理产品经销商行业中，个股表现普遍承压：卡地纳健康跌0.28%，麦克森药物批发跌2.03%，汉瑞祥涨0.32%，Datameds AI Inc跌11.44%，AdaptHealth Corp.跌1.59%。Cencora是全球最大的药品采购和分销服务公司之一，帮助医疗保健供应商以及制药和生物技术制造商改善患者获得产品、加强患者护理的机会，业务涵盖品牌药、专业品牌药及非专利药品的分销，以及数据分析、药房管理等增值服务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135373663","title":"异动解读｜Cencora盘前下跌3.22%，报307.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135373663","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135373663?lang=zh_cn&edition=full","pubTime":"2026-09-30 20:23","pubTimestamp":1790771008,"startTime":"0","endTime":"0","summary":"9月30日，Cencora盘前下跌3.22%，报307.72美元/股，成交额4.15万美元。Cencora所在的保健护理产品经销商行业中，个股表现分化：麦克森药物批发涨0%，卡地纳健康涨1.41%，汉瑞祥涨0%，AdaptHealth Corp.涨0%，Datameds AI Inc跌3.29%。Cencora是全球最大的药品采购和分销服务公司之一，帮助医疗保健供应商以及制药和生物技术制造商改善患者获得产品、加强患者护理的机会，业务涵盖品牌药、专业品牌药及非专利药品的分销，以及数据分析、药房管理等增值服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670230792","title":"高基数与银保新政双重施压，人身险累计保费增速年内首度转负","url":"https://stock-news.laohu8.com/highlight/detail?id=2670230792","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670230792?lang=zh_cn&edition=full","pubTime":"2026-09-28 20:49","pubTimestamp":1790599740,"startTime":"0","endTime":"0","summary":"人身险累计保费在8月由正转负。其中，人身险公司保费为3.57万亿元，呈现0.2%的负增长，这也是今年人身险公司累计保费口径首次出现负增长。连续两个月高于13%的单月保费负增长，也直接将累计保费拉入了负增长。受此催动，2025年8月单月人身险保费同比飙升近五成。非车险仍是财险增长引擎在人身险公司累计保费增速由正转负的背景下，前8个月行业保费增速均由财产险公司贡献。而在车险方面，累计保费则连续三个月呈现持平状态。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-09-28/doc-initkxux9619476.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-28/doc-initkxux9619476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2324357040.USD","LU1585245621.USD","SG9999004303.SGD","LU1119994496.HKD","BK4175","LU2237957811.SGD","COR","LU1814569148.SGD","LU0058720904.USD","LU2357627491.SGD","BK4585","LU1430594728.SGD","LU2237957902.USD","BK4588","BK4529","LU0289739699.SGD","LU0859254822.USD","LU1084165304.USD","LU1261432733.SGD","BK4084","SGXZ23171101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188730592","title":"异动解读｜Cencora盘中下跌3.77%，GLP-1产品组合对利润率的拖累持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1188730592","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188730592?lang=zh_cn&edition=full","pubTime":"2026-08-13 00:14","pubTimestamp":1786551265,"startTime":"0","endTime":"0","summary":"8月13日，Cencora盘中下跌3.77%，报321.285美元/股，成交额2.0亿美元。消息面上，公司此前发布的第三财季财报虽营收和盈利双双超预期，且上调全年EPS指引至17.75-17.95美元，但市场对GLP-1类药品组合对利润率的持续拖累表现出担忧。此外，公司CFO在电话会议中披露，若旗下MWI Animal Health与Covetrus合并完成，将面临约1.5亿美元营业利润逆风，进一步加剧了市场对盈利质量的疑虑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124411675","title":"异动解读｜Cencora盘中上涨3.78%，Q3业绩超预期并上调全年盈利指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1124411675","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124411675?lang=zh_cn&edition=full","pubTime":"2026-08-06 00:13","pubTimestamp":1785946389,"startTime":"0","endTime":"0","summary":"8月5日，Cencora盘中上涨3.78%，报317.86美元/股，成交额2.42亿美元。消息面上，公司当日盘前公布第三季度财报，业绩全面超出华尔街预期。数据显示，Q3调整后每股收益4.48美元，超出市场预期的4.35美元，同比增长12%；营收847.54亿美元，高于预期的843.15亿美元。公司此前已于3月宣布以11亿美元收购EyeSouth Partners视网膜业务，并与Kite达成CAR-T细胞疗法分销协议，持续深耕专业赛道。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199176119","title":"异动解读 | 业绩超预期并上调全年盈利指引，Cencora盘中大涨5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199176119","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199176119?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:34","pubTimestamp":1785936895,"startTime":"0","endTime":"0","summary":"Cencora今日盘中股价大幅拉升，涨幅达5.21%，引起市场广泛关注。消息面上，公司今日盘前公布了第三季度财报，业绩表现全面超出华尔街预期，并同步上调了全年盈利指引。基于此，Cencora将全年调整后每股收益预期上调至17.75至17.95美元，此前预期为17.65至17.90美元。此外，Cencora高管在电话会议中明确表示，公司的战略重心正聚焦于视网膜与肿瘤两大治疗领域，未来并购活动将严格围绕\"增值型补强式收购\"展开，而非盲目扩张。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["COR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155949747","title":"Cencora高管：聚焦视网膜与肿瘤领域，推进增值型“补强式”收购——电话会议纪要","url":"https://stock-news.laohu8.com/highlight/detail?id=1155949747","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155949747?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:25","pubTimestamp":1785936310,"startTime":"0","endTime":"0","summary":"在最新电话会议中，Cencora（COR）高管明确表示，公司的战略重心正锁定于视网膜与肿瘤两大治疗领域。他们强调，未来的并购活动将严格围绕“增值型补强式收购”展开。这种策略意在不偏离核心业务，通过精准补强，实现1+1>2的协同效应。高管们进一步阐释，此举旨在深化细分市场布局，而非盲目扩张。这一表态清晰勾勒出Cencora的资本配置路径，反映出其对专业赛道精耕细作的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004303.SGD","LU2237957811.SGD","LU0289739699.SGD","BK4175","BK4084","LU2237957902.USD","LU1585245621.USD","COR","SGXZ23171101.USD","LU1814569148.SGD","BK4585","LU1430594728.SGD","LU1084165304.USD","LU1261432733.SGD","BK4529","BK4588","LU2324357040.USD","LU0058720904.USD","LU1119994496.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657547004","title":"CENCORA高管：我们的重点是在视网膜和肿瘤领域进行增值性补强收购。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657547004","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657547004?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:24","pubTimestamp":1785936272,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0289739699.SGD","LU1585245621.USD","BK4175","LU2237957811.SGD","LU2237957902.USD","COR","BK4585","LU2324357040.USD","LU0058720904.USD","BK4529","BK4084","LU1430594728.SGD","BK4588","LU1084165304.USD","SG9999004303.SGD","SGXZ23171101.USD","LU1119994496.HKD","LU1814569148.SGD","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171083595","title":"Cencora首席财务官：Mwi Animal Health与Covetrus合并若完成，将带来1.5亿美元营业利润压力——电话会议实录","url":"https://stock-news.laohu8.com/highlight/detail?id=1171083595","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171083595?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:57","pubTimestamp":1785934632,"startTime":"0","endTime":"0","summary":"Cencora首席财务官在电话会议中透露，若Mwi Animal Health与Covetrus的合并交易最终达成，将面临约1.5亿美元的营业利润阻力。这一数字清晰地揭示了潜在整合中的财务挑战，也凸显了行业并购浪潮下的复杂博弈。尽管交易前景尚存变数，但Cencora高管已明确警示，合并带来的成本与整合压力不容小觑。投资者需密切关注这一动向，权衡潜在收益与风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU0058720904.USD","LU1119994496.HKD","LU1084165304.USD","LU1814569148.SGD","LU1430594728.SGD","BK4084","BK4175","LU2237957811.SGD","LU2237957902.USD","BK4529","SG9999004303.SGD","LU0289739699.SGD","BK4588","LU1585245621.USD","COR","BK4585","SGXZ23171101.USD","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118327421","title":"异动解读｜Cencora盘前上涨3.25%，多重利好催化持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1118327421","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118327421?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:19","pubTimestamp":1784294358,"startTime":"0","endTime":"0","summary":"7月17日，Cencora盘前上涨3.25%，报318.0美元/股，成交额540.03万美元。消息面上，近期多重利好持续催化。Evercore ISI于7月7日将公司目标价由300美元上调至330美元，维持跑赢大盘评级。此前，公司董事长Mark Durcan以每股266美元买入4000股、总额约100万美元，为其任期内金额最大的一次增持，被评为\"异常大额\"。同时，公司宣布恢复股票回购计划，授权规模高达20亿美元。此外，公司与吉利德旗下Kite达成CAR-T细胞疗法分销协议，进一步拓展专业药品分销业务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cencora盘前上涨3.25%，多重利好催化持续发酵","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146064750","title":"Cencora与Kite达成协议，支持其FDA批准的CAR-T细胞疗法Yescarta与Tecartus在美国的分销","url":"https://stock-news.laohu8.com/highlight/detail?id=1146064750","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146064750?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:06","pubTimestamp":1780401987,"startTime":"0","endTime":"0","summary":"Cencora Inc.宣布与吉利德科学旗下公司Kite达成一项协议，将支持Kite旗下两款已获美国食品药品监督管理局批准的CAR-T细胞疗法——Yescarta与Tecartus——在美国市场的分销工作。该合作旨在强化这些创新癌症疗法的供应链与可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","COR","LU0965509283.SGD","LU0889565916.HKD","LU1037948541.HKD","LU2324357040.USD","LU1261432733.SGD","LU1037948897.HKD","LU0114720955.EUR","SG9999015945.SGD","LU0823416689.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU1674673428.USD","BK4578","IE00B7SZLL34.SGD","LU1057294990.SGD","LU2237957902.USD","IE00BSNM7G36.USD","LU2112291526.USD","SGXZ23171101.USD","SG9999004303.SGD","BK4550","LU0965509101.SGD","LU2468319806.SGD","LU1571399168.USD","BK4568","LU1585245621.USD","LU1839511570.USD","LU0289739699.SGD","SG9999015952.SGD","LU1814569148.SGD","LU0965508806.USD","BK4585","LU1084165304.USD","LU0058720904.USD","BK4588","LU1674673691.USD","LU1778281490.HKD","BK4532","BK4139","SG9999015986.USD","LU1023059063.AUD","LU1066051498.USD","SG9999015978.USD","IE00BKVL7J92.USD","LU0109394709.USD","IE00B3T34201.USD","LU2087621335.USD","LU1430594728.SGD","LU1066053197.SGD","BK4529","LU1934455194.USD","GILD","IE00BZ1G4Q59.USD","LU2089984988.USD","IE0002270589.USD","LU0861579265.USD","BK4175","LU1119994496.HKD","LU1934455863.HKD","LU1061106388.HKD","LU2237957811.SGD","LU0122379950.USD","IE00B19Z3581.USD","LU0965509010.AUD","LU1934455277.USD","BK4084","LU0882574055.USD","LU0234570918.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185544530","title":"Cencora公司执行副总裁兼首席财务官James F. Cleary将退休，并担任顾问至2026年","url":"https://stock-news.laohu8.com/highlight/detail?id=1185544530","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185544530?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:56","pubTimestamp":1779879380,"startTime":"0","endTime":"0","summary":"Cencora公司宣布，其执行副总裁兼首席财务官James F. Cleary即将退休。在卸任后，他将以顾问身份继续为公司服务，直至2026年。这一高层人事变动标志着公司财务管理团队将迎来新的阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1261432733.SGD","COR","LU1084165304.USD","LU2237957811.SGD","LU1585245621.USD","LU2324357040.USD","SG9999004303.SGD","BK4588","LU0058720904.USD","LU0289739699.SGD","BK4175","LU1430594728.SGD","BK4585","BK4529","LU2237957902.USD","LU1119994496.HKD","SGXZ23171101.USD","LU1814569148.SGD","BK4084"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637087763","title":"市场资金在切换，这个方向或迎来大反攻？","url":"https://stock-news.laohu8.com/highlight/detail?id=2637087763","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637087763?lang=zh_cn&edition=full","pubTime":"2026-05-24 17:31","pubTimestamp":1779615119,"startTime":"0","endTime":"0","summary":"配置窗口已打开","market":"us","thumbnail":"https://img3.gelonghui.com/188dd-d6f762c2-8eff-462a-9cea-49f163ea266b.jpg?guru_height=963&guru_width=1280&guru_size=189784","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/188dd-d6f762c2-8eff-462a-9cea-49f163ea266b.jpg?guru_height=963&guru_width=1280&guru_size=189784"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4892658","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4529","BK4175","LU0058720904.USD","LU1261432733.SGD","LU0289739699.SGD","LU1585245621.USD","LU1814569148.SGD","SG9999004303.SGD","LU2324357040.USD","LU2237957902.USD","SGXZ23171101.USD","LU2237957811.SGD","LU1084165304.USD","BK4084","COR","LU1119994496.HKD","BK4588","LU1430594728.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176328074","title":"Cencora高管：公司看好管理服务组织业务的长期并购机遇——电话会议透露","url":"https://stock-news.laohu8.com/highlight/detail?id=1176328074","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176328074?lang=zh_cn&edition=full","pubTime":"2026-05-06 21:32","pubTimestamp":1778074353,"startTime":"0","endTime":"0","summary":"Cencora公司高管在最新电话会议中表示，随着时间推移，公司在其管理服务组织业务领域发现了大量优质的补强型收购机会。这一战略方向凸显了Cencora对该细分市场增长潜力的积极展望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237957811.SGD","BK4585","LU1585245621.USD","LU2237957902.USD","LU1084165304.USD","SG9999004303.SGD","COR","BK4529","BK4084","BK4175","LU0289739699.SGD","LU1814569148.SGD","LU1261432733.SGD","LU1119994496.HKD","BK4588","LU1430594728.SGD","LU2324357040.USD","LU0058720904.USD","SGXZ23171101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513790918","title":"【研报掘金｜华泰证券：上调中国再保险目标价至1.1港元 去年盈利超预期】华泰证券发表研究报告指，中国再保险预计2024年归母净利润按年升80%至100%，超出该行预期。该行认为，公司利润高速增长，或主要受投资业绩高增以及保险业务稳健增长的驱动。该行预计，集团2024年人身再保险业务净利润有望增长236%，2024年全年财险业务COR达99.8%。该行表示，考虑到投资波动，将上年、今年及明年每股盈测上调至分别0.25元、0.21元及0.21元，目标价则由1港元上调至1.1港元，维持其评级为“买入”。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513790918","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513790918?lang=zh_cn&edition=full","pubTime":"2025-02-24 13:49","pubTimestamp":1740376141,"startTime":"0","endTime":"0","summary":"华泰证券发表研究报告指，中国再保险预计2024年归母净利润按年升80%至100%，超出该行预期。该行认为，公司利润高速增长，或主要受投资业绩高增以及保险业务稳健增长的驱动。该行预计，集团2024年人身再保险业务净利润有望增长236%，2024年全年财险业务COR达99.8%。该行表示，考虑到投资波动，将上年、今年及明年每股盈测上调至分别0.25元、0.21元及0.21元，目标价则由1港元上调至1.1港元，维持其评级为“买入”。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24134948338990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01508","06886","COR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509764246","title":"【沃尔格林联合博姿继续出售Cencora股份 套现约3亿美元】 美国连锁药店沃尔格林联合博姿周四表示，已出售更多药品分销商Cencora的股份，套现约3亿美元。该公司目前在Cencora的持股比例从10%降至6%。此次出售股份所得将主要用于偿还债务和一般公司用途。（智通财经）","url":"https://stock-news.laohu8.com/highlight/detail?id=2509764246","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509764246?lang=zh_cn&edition=full","pubTime":"2025-02-07 14:41","pubTimestamp":1738910486,"startTime":"0","endTime":"0","summary":"美国连锁药店沃尔格林联合博姿周四表示，已出售更多药品分销商Cencora的股份，套现约3亿美元。该公司目前在Cencora的持股比例从10%降至6%。此次出售股份所得将主要用于偿还债务和一般公司用途。（智通财经）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/07144148009324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4128","LU2237957811.SGD","LU0321505868.SGD","LU1119994496.HKD","BK4175","LU1430594728.SGD","LU1084165304.USD","BK4529","COR","LU1261432733.SGD","BK4585","WBA","LU0321505439.SGD","SG9999004303.SGD","LU2324357040.USD","LU2237957902.USD","LU0058720904.USD","SGXZ23171101.USD","LU1585245621.USD","BK4588","BK4084","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126125390","title":"Cencora 第一季度财报：肥胖药物和特殊药品推动收入和每股收益超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1126125390","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126125390?lang=zh_cn&edition=full","pubTime":"2025-02-06 00:11","pubTimestamp":1738771872,"startTime":"0","endTime":"0","summary":"周三，Cencora, Inc公布其2025财年第一季度销售额增长12.8%，达到815亿美元，超过市场预期的783.8亿美元。公司报告的调整后每股收益为3.73美元，同比增长13.7%，超过市场预期的3.50美元。调整后的毛利润在2025年第一季度为25亿美元，比上一财年同期增长6.1%，这是由于两个报告部门的毛利润增加。Cencora预期调整后的摊薄每股收益为15.25至15.55美元，高于1月2日提供的15.15至15.45美元的范围以及最初的14.80至15.10美元的范围，市场预期为15.28美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COR","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509404970","title":"Cencora(COR.US)：2025年Q1财报实现营收814.87亿美元，前值为722.53亿美元，预期值为782.2亿美元；每股收益为3.73美元，前值为3.28美元，预期值为3.52美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509404970","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509404970?lang=zh_cn&edition=full","pubTime":"2025-02-05 19:46","pubTimestamp":1738755995,"startTime":"0","endTime":"0","summary":"Cencora(COR.US)：2025年Q1财报实现营收814.87亿美元，前值为722.53亿美元，预期值为782.2亿美元；每股收益为3.73美元，前值为3.28美元，预期值为3.52美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/05194647966049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["COR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158459761","title":"Cencora 2025年第一季度调整后每股收益$3.73，超过预期的$3.50，销售额为$814.9亿，超过预期的$783.8亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1158459761","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158459761?lang=zh_cn&edition=full","pubTime":"2025-02-05 19:32","pubTimestamp":1738755166,"startTime":"0","endTime":"0","summary":"Cencora 报告其季度每股收益为$3.73，超过分析师普遍预期的$3.50，超出6.57%。与去年同期每股收益$3.28相比增长了13.72%。以上内容来自Benzinga Earnings专栏，原文如下：Cencora reported quarterly earnings of $3.73 per share which beat the analyst consensus estimate of $3.50 by 6.57 percent. This is a 13.72 percent increase over earnings of $3.28 per share from the same period last year. The company reported quarterly sales of $81.49 billion which beat the analyst consensus estimate of $78.38 billion by 3.96 percent. This is a 12.78 percent increase over ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cencora 2025年第一季度调整后每股收益$3.73，超过预期的$3.50，销售额为$814.9亿，超过预期的$783.8亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507682115","title":"富国银行：维持Cencora(COR.US)评级，由持股观望调整至持股观望评级, 目标价由237.00美元调整至251.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507682115","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507682115?lang=zh_cn&edition=full","pubTime":"2025-01-29 19:53","pubTimestamp":1738151599,"startTime":"0","endTime":"0","summary":"富国银行：维持Cencora(COR.US)评级，由持股观望调整至持股观望评级, 目标价由237.00美元调整至251.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/29195347897048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["COR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cencora.com;investor.cencora.com","stockEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.0448},{"period":"3month","weight":0.0665},{"period":"6month","weight":-0.053},{"period":"1year","weight":-0.0015},{"period":"ytd","weight":-0.0893}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0067},{"period":"3month","weight":0.0247},{"period":"6month","weight":0.1652},{"period":"1year","weight":0.1515},{"period":"ytd","weight":0.1207}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cencora, Inc.于2001年3月在特拉华州注册成立。作为全球最大的药品采购和分销服务公司之一，帮助医疗保健供应商以及制药和生物技术制造商改善患者获得产品加强患者护理的机会。该公司提供创新计划和服务，旨在提高药品供应链在人类和动物健康方面的效力和效率。更具体地说，该公司向位于美国和部分全球市场的各种医疗保健提供商提供全面的品牌、专业品牌和非专利药品、非处方医疗产品、家庭医疗用品和设备以及相关服务，包括急性病医院和卫生系统、独立和连锁零售药店、邮购药房、诊所、长期护理和替代地点药房、医师执业、医疗和透析诊所、兽医和其他客户。此外，公司还为医疗保健提供商和制药制造商提供各种相关服务，包括数据分析、结果研究、报销和药物咨询服务、利基优质物流服务、库存管理、药房自动化、药房管理和包装解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.050015},{"month":2,"riseRate":0.566667,"avgChangeRate":-0.001172},{"month":3,"riseRate":0.566667,"avgChangeRate":0.003647},{"month":4,"riseRate":0.566667,"avgChangeRate":0.015179},{"month":5,"riseRate":0.6,"avgChangeRate":0.019188},{"month":6,"riseRate":0.548387,"avgChangeRate":0.029797},{"month":7,"riseRate":0.580645,"avgChangeRate":0.015407},{"month":8,"riseRate":0.612903,"avgChangeRate":-0.008092},{"month":9,"riseRate":0.516129,"avgChangeRate":0.022334},{"month":10,"riseRate":0.566667,"avgChangeRate":-0.006226},{"month":11,"riseRate":0.7,"avgChangeRate":0.032788},{"month":12,"riseRate":0.533333,"avgChangeRate":0.013707}],"exchange":"NYSE","name":"CENCORA","nameEN":"Cencora Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CENCORA(COR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供CENCORA(COR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"CENCORA,COR,CENCORA股票,CENCORA股票老虎,CENCORA股票老虎国际,CENCORA行情,CENCORA股票行情,CENCORA股价,CENCORA股市,CENCORA股票价格,CENCORA股票交易,CENCORA股票购买,CENCORA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CENCORA(COR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供CENCORA(COR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}